AR and cancer: Thus, in both PCa and BCa, AR signaling appears to regulate distinct sets of target genes in hormone-dependent cancers (i.e., hormone-naïve PCa, ER+ BCa) and hormone-refractory cancers (i.e., CRPC, ER− BCa, hormone therapy-resistant ER+ BCa).